1. Home
  2. ZLAB vs TARS Comparison

ZLAB vs TARS Comparison

Compare ZLAB & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

HOLD

Current Price

$18.35

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Logo Tarsus Pharmaceuticals Inc.

TARS

Tarsus Pharmaceuticals Inc.

HOLD

Current Price

$60.39

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZLAB
TARS
Founded
2013
2016
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.7B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
ZLAB
TARS
Price
$18.35
$60.39
Analyst Decision
Strong Buy
Buy
Analyst Count
5
6
Target Price
$49.60
$89.00
AVG Volume (30 Days)
598.6K
504.6K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
38.46
48.21
EPS
N/A
N/A
Revenue
$460,156,000.00
$451,360,000.00
Revenue This Year
$9.75
$56.43
Revenue Next Year
$26.03
$30.19
P/E Ratio
N/A
N/A
Revenue Growth
15.33
146.71
52 Week Low
$15.96
$38.51
52 Week High
$44.34
$85.25

Technical Indicators

Market Signals
Indicator
ZLAB
TARS
Relative Strength Index (RSI) 35.16 35.83
Support Level $16.88 $48.20
Resistance Level $19.64 $76.47
Average True Range (ATR) 0.95 3.40
MACD -0.51 -0.02
Stochastic Oscillator 0.22 16.43

Price Performance

Historical Comparison
ZLAB
TARS

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Share on Social Networks: